2026年2月6日 抄読会
担当 池田
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
T M Maher, J G Goldin, J Hood, J Pitman, M de Los Rios, B P Hobbs, A B Yu-Lin, I Buendia-Roldan, F Thien, J W Song, P C Perea, A Ramírez-Rivera, A DiFrancesco
Lancet Respir Med. 2025 Nov;13(11):1001-1010. doi: 10.1016/S2213-2600(25)00239-5.
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
T M Maher, J G Goldin, J Hood, J Pitman, M de Los Rios, B P Hobbs, A B Yu-Lin, I Buendia-Roldan, F Thien, J W Song, P C Perea, A Ramírez-Rivera, A DiFrancesco
Lancet Respir Med. 2025 Nov;13(11):1001-1010. doi: 10.1016/S2213-2600(25)00239-5.